Liver and Diabetes. A Vicious Circle

Overview

Journal Hepatol Res

Specialty Gastroenterology

Date 2013 Jan 22

PMID 23332087

Citations 102

Authors

Paola Loria

Amedeo Lonardo

Frank Anania

Affiliations

Soon will be listed here.

Abstract

The complex and bi-directional relationship linking the liver and diabetes has recently gained intense new interest. This critical review of the published work aims to highlight the most recent basic and clinical data underlying the development of type 2 diabetes, in those with non-alcoholic fatty liver disease. Moreover, the potentially detrimental effects of type 2 diabetes in liver injury are also discussed in each of the two sections of the present paper. Fatty liver and diabetes share insulin resistance as their chief pathogenic determinant. The roles of the hypothalamus, the intestinal microbiome, white adipose tissue and inflammation are discussed in detail. Molecular insights into hepatocyte insulin resistance as the initiator of systemic insulin resistance are also presented with full coverage of the danger of fatty acids. Lipotoxicity, apoptosis, lipoautophagy, endoplasmic reticular stress response and recent developments in genetics are discussed. Closing the circle, special emphasis is given to biochemical pathways and clinical evidence supporting the role of type 2 diabetes as a risk factor for the development of progressive liver disease, including non-alcoholic steatohepatitis, cirrhosis and primary liver cancer. In conclusion, data support non-alcoholic fatty liver disease as a risk factor for the development of type 2 diabetes which is, in turn, a major contributor to progressive liver disease. This pathway leading from fatty liver to type 2 diabetes and back from the latter to the progressive liver disease is a vicious circle.

Citing Articles

ZBiotics ameliorates T2DM-induced histopathological damage in liver, kidney and adipose tissues by modulating the NOD-like receptor signaling in Wistar rats.

Esawie M, Matboli M, Bushra M, Hasanin A, Habib E, Mohamed R Diabetol Metab Syndr. 2025; 17(1):45.

PMID: 39905472 PMC: 11792315. DOI: 10.1186/s13098-025-01600-3.

Exosomes Derived from Adipose Mesenhymal Stem Cells Ameliorate Lipid Metabolism Disturbances Following Liver Ischemia-Reperfusion Injury in Miniature Swine.

Lu X, Wang Y, Piao C, Li P, Cao L, Liu T Int J Mol Sci. 2024; 25(23).

PMID: 39684778 PMC: 11641803. DOI: 10.3390/ijms252313069.

Controlled release of hydrogel-encapsulated mesenchymal stem cells-conditioned medium promotes functional liver regeneration after hepatectomy in metabolic dysfunction-associated steatotic liver disease.

Kasahara N, Teratani T, Doi J, Yokota S, Shimodaira K, Kaneko Y Stem Cell Res Ther. 2024; 15(1):395.

PMID: 39497124 PMC: 11536549. DOI: 10.1186/s13287-024-03993-w.

Exploring the Biological Effects of Anti-Diabetic Vanadium Compounds in the Liver, Heart and Brain.

Dayanand Y, Pather R, Xulu N, Booysen I, Sibiya N, Khathi A Diabetes Metab Syndr Obes. 2024; 17:3267-3278.

PMID: 39247428 PMC: 11380877. DOI: 10.2147/DMSO.S417700.

Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease.

Bea S, Ko H, Bae J, Cho Y, Chang Y, Ryu S Gut. 2024; 74(2):284-294.

PMID: 39242193 PMC: 11874371. DOI: 10.1136/gutjnl-2024-332687.

References

Fliers E, Kreier F, Voshol P, Havekes L, Sauerwein H, Kalsbeek A . White adipose tissue: getting nervous. J Neuroendocrinol. 2003; 15(11):1005-10. DOI: 10.1046/j.1365-2826.2003.01096.x. View

Puri P, Mirshahi F, Cheung O, Natarajan R, Maher J, Kellum J . Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2007; 134(2):568-76. DOI: 10.1053/j.gastro.2007.10.039. View

El-Serag H, Tran T, Everhart J . Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004; 126(2):460-8. DOI: 10.1053/j.gastro.2003.10.065. View

Considine R, Nyce M, Allen L, Morales L, Triester S, Serrano J . Protein kinase C is increased in the liver of humans and rats with non-insulin-dependent diabetes mellitus: an alteration not due to hyperglycemia. J Clin Invest. 1995; 95(6):2938-44. PMC: 295982. DOI: 10.1172/JCI118001. View

Younossi Z, Gramlich T, Matteoni C, Boparai N, McCullough A . Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004; 2(3):262-5. DOI: 10.1016/s1542-3565(04)00014-x. View

Al-Haddad M, Khashab M, Zyromski N, Pungpapong S, Wallace M, Scolapio J . Risk factors for hyperechogenic pancreas on endoscopic ultrasound: a case-control study. Pancreas. 2009; 38(6):672-5. DOI: 10.1097/MPA.0b013e3181a9d5af. View

Kantartzis K, Gastaldelli A, Magkos F, Lavoie J . Diabetes and nonalcoholic fatty liver disease. Exp Diabetes Res. 2011; 2012:404632. PMC: 3238359. DOI: 10.1155/2012/404632. View

Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J . Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257(1):79-83. DOI: 10.1006/bbrc.1999.0255. View

Lin W, Xaiver Pi-Sunyer F, Chen C, Davidson L, Liu C, Li T . Coffee consumption is inversely associated with type 2 diabetes in Chinese. Eur J Clin Invest. 2011; 41(6):659-66. PMC: 3087821. DOI: 10.1111/j.1365-2362.2010.02455.x. View

10.

Lonardo A, Carulli N, Loria P . HCV and diabetes. A two-question-based reappraisal. Dig Liver Dis. 2007; 39(8):753-61. DOI: 10.1016/j.dld.2007.05.005. View

11.

Kumashiro N, Erion D, Zhang D, Kahn M, Beddow S, Chu X . Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2011; 108(39):16381-5. PMC: 3182681. DOI: 10.1073/pnas.1113359108. View

12.

Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette J, Diehl A . Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008; 48(6):993-9. PMC: 2423467. DOI: 10.1016/j.jhep.2008.02.011. View

13.

Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I . Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab. 2011; 96(8):2601-8. DOI: 10.1210/jc.2010-2415. View

14.

Vijay-Kumar M, Aitken J, Carvalho F, Cullender T, Mwangi S, Srinivasan S . Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010; 328(5975):228-31. PMC: 4714868. DOI: 10.1126/science.1179721. View

15.

Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K . The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143(10):722-8. DOI: 10.7326/0003-4819-143-10-200511150-00009. View

16.

Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N . Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364(9):829-841. PMC: 4109980. DOI: 10.1056/NEJMoa1008862. View

17.

Hanley A, Williams K, Festa A, Wagenknecht L, DAgostino Jr R, Haffner S . Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005; 54(11):3140-7. DOI: 10.2337/diabetes.54.11.3140. View

18.

Karmi A, Iozzo P, Viljanen A, Hirvonen J, Fielding B, Virtanen K . Increased brain fatty acid uptake in metabolic syndrome. Diabetes. 2010; 59(9):2171-7. PMC: 2927939. DOI: 10.2337/db09-0138. View

19.

Vozarova B, Stefan N, Lindsay R, Saremi A, Pratley R, Bogardus C . High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002; 51(6):1889-95. DOI: 10.2337/diabetes.51.6.1889. View

20.

. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011; 60(50):1709-11. View